Who owns ENANTA PHARMACEUTICALS INC (ENTA)? Elite investor 13F holders
2 tracked elite investors reported holding ENANTA PHARMACEUTICALS INC as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | ENANTA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 8129808.00 USD | 557600.000000 | Shares | reduce | Original filing |
| D.E. Shaw | ENANTA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 503579.00 USD | 34539.000000 | Shares | reduce | Original filing |
| Tudor Investment | ENANTA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.